Mooney Marc E, Poling James, Gonzalez Gerardo, Gonsai Kishor, Kosten Thomas, Sofuoglu Mehmet
Department of Psychiatry, Transdisciplinary Tobacco Use Research Center, University of Minnesota, Minneapolis, Minnesota 55414, USA.
Am J Addict. 2008 Jul-Aug;17(4):287-92. doi: 10.1080/10550490802138814.
In this double-blind, placebo-controlled trial, bupropion (BUPRO, 300 mg/day) was compared to placebo (PBO) for the concurrent treatment of opioid and tobacco addiction in 40 opioid-dependent smokers stabilized on buprenorphine (BUPRE, 24 mg/day). Participants received contingent, monetary reinforcement for abstinence from smoking, illicit opioids, and cocaine. Significant differences in treatment retention were observed (BUPRE+BUPRO, 58%; BUPRE+PBO, 90%). BUPRO treatment was not more effective than placebo for abstinence from tobacco, opioids, or cocaine in BUPRE-stabilized patients. These preliminary findings do not support the efficacy of BUPRO, in combination with BUPRE, for the concurrent treatment of opioid and tobacco addiction.
在这项双盲、安慰剂对照试验中,将安非他酮(BUPRO,300毫克/天)与安慰剂(PBO)进行比较,以同时治疗40名依赖阿片类药物且已使用丁丙诺啡(BUPRE,24毫克/天)稳定治疗的吸烟者的阿片类药物和烟草成瘾问题。参与者因戒烟、戒除非法阿片类药物和可卡因而获得意外的金钱奖励。观察到治疗保留率存在显著差异(BUPRE+BUPRO组为58%;BUPRE+PBO组为90%)。在使用BUPRE稳定治疗的患者中,BUPRO治疗在戒烟、戒除阿片类药物或可卡因方面并不比安慰剂更有效。这些初步研究结果不支持BUPRO与BUPRE联合用于同时治疗阿片类药物和烟草成瘾的疗效。